Uso de cariprazina en el trastorno bipolar: una revisión sistemática y aspectos prácticos

Abstract

Cariprazine is a new generation antipsychotic that acts as a partial agonist of dopamine D2 and D3 receptors and serotonin 5HT1A receptors.

Cariprazine has now been approved by the Spanish Medicines Association (Asociación Española del Medicamento (AEM)) for the treatment of schizophrenia, and by the Food and Drug Administration (FDA) for the treatment of the manic, depressive, and mixed states associated with bipolar disorder (BD). The available scientific evidence, and several international guidelines attest to the efficacy, safety, and tolerability of this drug and endorse its use in any type of acute BD episode, with or without mixed symptoms.

The most frequent adverse effects are extrapyramidal symptoms, especially akithisia. Studies propose individualising the dose of cariprazine to the type and severity of the episode, and the patient’s tolerability. The most recent studies also seem to indicate a potential benefit in the prevention of relapse in the euthymia phase, and clinical trials are currently underway to evaluate this and the impact of the drug on patients’ cognitive sphere and functionality. To conclude, the use of cariprazine in bipolar disorder is fully justified from a scientific perspective, with overall benefits that far outweigh the adverse effects profile.